Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) variants and breast cancer risk in Burkina Faso

• Published in: Biomolecular concepts Vol. 10; no. 1; p. 175
• Main Authors: Kiendrebeogo, Isabelle Touwendpoulimdé, Zoure, Abdou Azaque, Sorgho, Pegdwendé Abel, Yonli, Albert Théophane, Djigma, Florencia Wendkuuni, Ouattara, Abdoul Karim, Sombie, Herman Karim, Tovo, Sessi Frida, Yelemkoure, Edwige T, Bambara, Aboubacar Hierrhum, Sawadogo, Alexis Yobi, Bakri, Youssef, Simpore, Jacques
• Format: Journal Article
• Language: English
• Published: Germany 09.11.2019
• Subjects: Adult; Aged; Breast Neoplasms - genetics; Burkina Faso; Female; Glutathione Transferase - genetics; Humans; Loss of Function Mutation; Middle Aged; Polymorphism, Single Nucleotide; Burkina Faso; Breast cancer risk; Burkina Faso; GSTM1-GSTT1; Genotypes
• ISSN: 1868-503X

Background and objective Breast cancer remains the most common cause of cancer mortality in women. The aim of this study was to investigate associations between genetic variability in GSTM1 and GSTT1 and susceptibility to breast cancer. Methods Genomic DNA was extracted from blood samples for 80 cases of histologically diagnosed breast cancer and 100 control subjects. Genotyping analyses were performed by PCR-based methods. Associations between specific genotypes and the development of breast cancer were examined using logistic regression to calculate odds ratios [1] and 95% confidence intervals (95%CI). Results No correlation was found between GSTM1-null and breast cancer (OR = 1.83; 95%CI 0.90-3.71; p = 0.10), while GSTT1-null (OR = 2.42; 95%CI 1.17-5.02; p= 0.01) was associated with increased breast cancer risk. The GSTM1/GSTT1 double null was not associated with an increased risk of developing breast cancer (OR = 2.52; 95%CI 0.75-8.45; p = 0.20). Furthermore, analysis found no association between GSTM1-null (OR =1.12; 95%CI 0.08-15.50; p = 1.00) or GSTT1-null (OR = 1.71; 95%CI 0.13-22.51; p = 1.00) and the disease stage of familial breast cancer patients or sporadic breast cancer patients (GSTM1 (OR = 0.40; 95%CI 0.12-1.32; p = 0.20) and GSTT1 (OR = 1.41; 95%CI 0.39-5.12; p = 0.75)). Also, body mass index (BMI) was not associated with increased or decreased breast cancer risk in either GSTM1-null (OR = 0.60; 95%CI 0.21-1.68; p = 0.44) or GSTT1-null (OR = 0.60; 95%CI 0.21-1.68; p =0.45). Conclusion Our results suggest that only GSTT1-null is associated with increased susceptibility to breast cancer development.